Venture Funding Deals: Innovent Sets Financing Record In China
• By Deanna Kamienski, Beth Allan, Maureen Riordan, and Steven Muntner
The firm’s $260m Series D is the largest ever for biopharma in China and one of the biggest of the year worldwide; other notable financings go to Biohaven, Kymab and Magenta. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced October through early December.
Danish firm Acesion Pharma APS, specializing in therapies for atrial fibrillation, raised €9.1m ($10m) in the first close of what appears to be a third round to current investors Wellcome Trust and Novo Seeds. (Nov.)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
Start-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.
Lead drug GLM101 will move into its first placebo-controlled trial based on positive results in adults and adolescents with PMM2-CDG in an open-label Phase IIa study.
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.
